Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1

INTRODUCTION: To improve the standard treatment paradigm for glioblastoma (GBM), efforts have been made to explore the efficacy of epigenetic agents as chemosensitizers. Recent data suggest possible synergy between decitabine (DAC), a DNA hypomethylating agent, and temozolomide (TMZ) in GBM, but the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Neurooncol
Main Authors: Gallitto, Matthew, Cheng He, Rossana, Inocencio, Julio F., Wang, Huaien, Zhang, Yizhou, Deikus, Gintaras, Wasserman, Isaac, Strahl, Maya, Smith, Melissa, Sebra, Robert, Yong, Raymund L.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2020
Teme:
Laboratory Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7256087/
https://ncbi.nlm.nih.gov/pubmed/32193690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-020-03461-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki